Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

N4-Pharma company presentation june 24.pdf

We are excited to share our latest corporate presentation, detailing our innovative nanoparticle delivery systems for cancer treatments, gene therapy, and vaccines. This presentation highlights our key projects and strategic collaborations. The company is advancing research on dual-loading siRNA for cancer resistance, oral delivery, and enhancing viral vectors. Ongoing collaborations with SRI International and potential licensing opportunities aim to strengthen their position in the biotech market.

We invite all investors to review the presentation and engage with us by submitting any questions. Our team is committed to helping you understand our advancements and the potential impact on the biotech market.

Engage with us by submitting your questions and let us help you understand our progress.

N4 Pharma Company Presentation June 24